Aggressive advanced gastric cancer in a patient with autosomal dominant polycystic kidney disease.
Autosomal dominant polycystic kidney disease
Gastric cancer
Mechanistic target of rapamycin
PKD-1 gene
Polycystin-1
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
18
11
2020
accepted:
23
03
2021
pubmed:
25
5
2021
medline:
27
7
2021
entrez:
24
5
2021
Statut:
ppublish
Résumé
A 60-year-old man with autosomal dominant polycystic kidney disease presented with malaise, melena, and epigastric discomfort. Esophagogastroduodenoscopy revealed a massive elevated gastric cancer lesion involving the cardia. Histopathological evaluation of a biopsy specimen showed poorly differentiated adenocarcinoma. Fluorodeoxyglucose-positron emission tomography revealed significant fluorodeoxyglucose uptake in the stomach, liver, bones, and bone marrow. He was diagnosed with metastatic gastric cancer resistant to chemotherapy, and he developed bone marrow carcinomatosis and disseminated intravascular coagulation and died 8 weeks after disease onset. A statistically significant association is reported between autosomal dominant polycystic kidney disease and gastric cancer. Moreover, the specific clinical features observed in our patient could be attributed to the molecular disorders like PC-1 and mechanistic target of rapamycin that are known to occur in autosomal dominant polycystic kidney disease.
Identifiants
pubmed: 34028786
doi: 10.1007/s12328-021-01407-5
pii: 10.1007/s12328-021-01407-5
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1014-1019Informations de copyright
© 2021. Japanese Society of Gastroenterology.
Références
Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2013;17:317–26.
doi: 10.1007/s10157-012-0741-0
Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4:50.
doi: 10.1038/s41572-018-0047-y
Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359:1477–85.
doi: 10.1056/NEJMcp0804458
The European Polycystic Kidney D. The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. Cell. 1994;77:881–94.
doi: 10.1016/0092-8674(94)90137-6
Huan Y, van Adelsberg J. Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins. J Clin Invest. 1999;104:1459–68.
doi: 10.1172/JCI5111
Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333–9.
doi: 10.1016/S0002-9440(10)65575-7
Boletta A, Qian F, Onuchic LF, et al. Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol Cell. 2000;6:1267–73.
doi: 10.1016/S1097-2765(00)00123-4
Zhang K, Ye C, Zhou Q, et al. PKD1 inhibits cancer cells migration and invasion via Wnt signaling pathway in vitro. Cell Biochem Funct. 2007;25:767–74.
doi: 10.1002/cbf.1417
Yu T-M, Chuang Y-W, Yu M-C, et al. Risk of cancer in patients with polycystic kidney disease: a propensity-score matched analysis of a nationwide, population-based cohort study. Lancet Oncol. 2016;17:1419–25.
doi: 10.1016/S1470-2045(16)30250-9
Sun K, Xu D, Mei C. The association between autosomal dominant polycystic kidney disease and cancer. Int Urol Nephrol. 2019;51:93–100.
doi: 10.1007/s11255-018-1951-5
Wilson PD. Polycystic kidney disease. N Engl J Med. 2004;350:151–64.
doi: 10.1056/NEJMra022161
Hughes J, Ward CJ, Peral B, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet. 1995;10:151–60.
doi: 10.1038/ng0695-151
Scheffers MS, van der Bent P, Prins F, et al. Polycystin-1, the product of the polycystic kidney disease 1 gene, co-localizes with desmosomes in MDCK cells. Hum Mol Genet. 2000;9:2743–50.
doi: 10.1093/hmg/9.18.2743
Basora N, Tetreault MP, Boucher MP, et al. Polycystin-1 is a microtubule-driven desmosome-associated component in polarized epithelial cells. Exp Cell Res. 2010;316:1454–64.
doi: 10.1016/j.yexcr.2010.02.033
Wheatley DN. Primary cilia in normal and pathological tissues. Pathobiology. 1995;63:222–38.
doi: 10.1159/000163955
Wilson PD. Polycystin: new aspects of structure, function, and regulation. J Am Soc Nephrol. 2001;12:834–45.
doi: 10.1681/ASN.V124834
Hogan MC, Manganelli L, Woollard JR, et al. Characterization of PKD protein-positive exosome-like vesicles. J Am Soc Nephrol. 2009;20:278–88.
doi: 10.1681/ASN.2008060564
Stone J, Bevan S, Cunningham D, et al. Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer. Br J Cancer. 1999;79:1935–7.
doi: 10.1038/sj.bjc.6690308
Lin CC, Kurashige M, Liu Y, et al. A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. Sci Rep. 2018;8:2743.
doi: 10.1038/s41598-018-20856-6
Kito Y, Saigo C, Takeuchi T. Novel transgenic mouse model of polycystic kidney disease. Am J Pathol. 2017;187:1916–22.
doi: 10.1016/j.ajpath.2017.05.002
Takeuchi T, Adachi Y, Nagayama T. A WWOX-binding molecule, transmembrane protein 207, is related to the invasiveness of gastric signet-ring cell carcinoma. Carcinogenesis. 2012;33:548–54.
doi: 10.1093/carcin/bgs001
Margaria JP, Campa CC, De Santis MC, et al. The PI3K/Akt/mTOR pathway in polycystic kidney disease: a complex interaction with polycystins and primary cilium. Cell Signal. 2020;66:109468.
doi: 10.1016/j.cellsig.2019.109468
Shillingford JM, Piontek KB, Germino GG, et al. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol. 2010;21:489–97.
doi: 10.1681/ASN.2009040421
Murugan AK. mTOR: role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019;59:92–111.
doi: 10.1016/j.semcancer.2019.07.003
Yu G, Wang J, Chen Y, et al. Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of Chinese patients with gastric cancer. Clin Cancer Res. 2009;15:1821–9.
doi: 10.1158/1078-0432.CCR-08-2138
Aziz SA, Ahmad M, Shah A. Carcinoma of the gastroesophageal junction associated with adult polycystic kidney disease. Nephron. 1998;79:362–3.
doi: 10.1159/000045070
Tsukayama S, Yamamura K. A case of gastric cancer with polycystic kidney. Nihon Rinsho Geka Gakkai Zasshi (J Jpn Surg Assoc). 2002;63:375–8.
doi: 10.3919/jjsa.63.375
Yamanaka H, Asamoto H, Ishizaka T, et al. A case of gastric cancer with autosomal dominant polycystic kidney disease. Jpn J Gastroenterol Surg. 2010;43:628–34.
doi: 10.5833/jjgs.43.628
Mimatsu K, Oida T, Kawasaki A, et al. Multiple gastric carcinomas associated with potter type III cystic disease. Case Rep Gastroenterol. 2011;5:590–6.
doi: 10.1159/000329179
Chen YC, Fang WL, Wang RF, et al. Clinicopathological variation of lauren classification in gastric cancer. Pathol Oncol Res. 2016;22:197–202.
doi: 10.1007/s12253-015-9996-6